Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Litigation
Patents
PipCast®
PTE
Webinars
  • Our Awards
  • Our Capabilities
  • Our People
    • Naomi Pearce
    • Eliza Jane Saunders
    • Jacinta Flattery-O’Brien PhD
    • Chris Vindurampulle PhD
    • Anna Stines PhD
    • Kate Legge
    • Adele Chadwick
    • Christopher Coates
    • Lesley White
    • Matthew Wilson
    • Donna Meredith
    • Sian Hope
    • Emily Dwyer
    • Brittany Deleon
    • Robin Smith
    • Mark Scully
  • Blog
  • BioBlast®
  • E-Books
    • Australia’s Rocket Patent Register: From Application to Patent in a Few Months
    • Entering National Phase in Australia
    • Exclusive Licences
    • Patent linkage in Australia and New Zealand
    • Patent Litigation in Australia
    • Pharmaceutical Patent Term Extensions (PTE) in Australia
    • The 2-Minute Guide to Australian Patent Oppositions
    • The one-minute guide to life sciences patent eligibility in the US, Europe and Australia
    • Australian Patent Cases Review 2021
    • Patent Re-Examination in Australia
  • Webinars
  • Diversity
  • Careers
  • Contact Us

Home / News / BioBlast®

FDA approves Eli Lilly’s Rezvlogar® (biosimilar insulin glargine)

Dec 20, 2021

The FDA approved Eli Lilly’s Rezvlogar® (biosimilar insulin glargine).

  • LinkedIn
Print Page Mail Article
View all BioBlast® Updates

Product specific reports based on extracts from our BioBlast® database

adalimumab | Humira® | AbbVie

aflibercept | Eylea® | Regeneron

bevacizumab | Avastin® | Roche/Genentech

cetuximab | Erbitux® | BMS/Merck

darbepoetin | Aranesp® | Amgen

denosumab | Prolia®/Xgeva® | Amgen

dupilumab | Dupixent® | Sanofi-Aventis

eculizumab | Soliris® | Alexion

etanercept | Enbrel® | Amgen

faricimab | Vabysmo® | Roche

filgrastim (GCSF) | Neupogen® | Amgen

golimumab | Simponi® | Janssen

guselkumab | Tremfya® | Janssen

infliximab | Remicade® | Johnson & Johnson

ixekizumab | Taltz® | Eli Lilly

natalizumab | Tysabri® | Biogen/Elan

omalizumab | Xolair® | Genentech / Novartis

pegfilgrastim | Neulasta® | Amgen

pembrolizumab | Keytruda® | Merck

pertuzumab | Perjeta® | Roche

ranibizumab | Lucentis® | Genentech

regdanvimab | Regkirona® | Celltrion

risankizumab | Skyrizi® | AbbVie

rituximab | Rituxan®/MabThera® | Genentech/Biogen

secukinumab | Cosentyx® | Novartis

tocilizumab | Actemra® | Roche

trastuzumab | Herceptin® | Roche/Genentech

ustekinumab | Stelara® | Johnson & Johnson

View latest BioBlast® updates

Biosimilars Deals

2023 Deals

2022 Deals

2021 Deals

2020 Deals

2019 Deals

2018 Deals

SUBSCRIBE TO PEARCE IP

Sign up to receive the latest life sciences industry news

Receive our weekly BioBlast®, regular life sciences Industry News and other Pearce IP updates straight to your inbox.

SUBSCRIBE
  • Our People
  • Our Capabilities
  • News
  • Blog
  • BioBlast®
  • Contact Us
  • Follow
Copyright © Pearce IP. All Rights Reserved. Privacy Statement
Manage Cookie Consent
We use cookies to optimise our website and our service.
Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
Manage options Manage services Manage vendors Read more about these purposes
Preferences
{title} {title} {title}